Manufacturer of Controlled Substances; Notice of Application, 65789 [E9-29527]

Download as PDF Federal Register / Vol. 74, No. 237 / Friday, December 11, 2009 / Notices by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule jlentini on DSKJ8SOYB1PROD with NOTICES Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... 4-Bromo-2, 5dimethoxyamphetamine. (7391) ........................................... 3, 4Methylenedioxymethamphetamine. (7405) ........................................... Amphetamine (1100) .................... Phencyclidine (7471) .................... Cocaine (9041) ............................. Diprenorphine (9058) ................... Fentanyl (9801) ............................ I I I 17:33 Dec 10, 2009 DEPARTMENT OF JUSTICE Dated: December 1, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–29542 Filed 12–10–09; 8:45 am] Office of Justice Programs BILLING CODE 4410–09–P I Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application II II II II II Jkt 220001 [OJP (NIJ) Docket No. 1510] Vehicular Digital Multimedia Evidence Recording System Standard Special Technical Committee AGENCY: DEPARTMENT OF JUSTICE The company plans to import small quantities of the above listed controlled substances for non-clinical, laboratorybased research only. In reference to drug code 7360 (Marihuana), the company plans to import synthetic cannabinoid agonists. In reference to drug code 7370 (Tetrahydrocannabinols), the company will import a synthetic Delta–9–THC. No other activity for these drug codes are authorized for this registration. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than January 11, 2010. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 VerDate Nov<24>2008 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. 65789 Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 28, 2009, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule Tetrahydrocannabinols (7370) ..... Dihydromorphine (9145) ............... Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ I I II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. In reference to drug code 7370 the company plans to bulk manufacture a synthetic Tetrahydrocannabinol. No other activity for this drug code is authorized for this registration. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than February 9, 2010. Dated: December 1, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–29527 Filed 12–10–09; 8:45 am] BILLING CODE 4410–09–P PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 National Institute of Justice. ACTION: Notice of request for proposals for certification and testing expertise. SUMMARY: The National Institute of Justice (NIJ) is in the process of developing a new Vehicular Digital Multimedia Evidence Recording System Standard and corresponding certification program requirements. This work is being performed by a Special Technical Committee (STC), comprised of practitioners from the field, researchers, testing experts, certification experts, and representatives from stakeholder organizations. It is anticipated that the STC members will participate in six 2-day meetings over a 9-month time period with the goal of completing development of the standard and certification program requirements. It is anticipated that STC meetings will begin in mid-January 2010. Travel expenses and per diem will be reimbursed for all STC meetings; however, participation time will not be funded. NIJ is seeking representatives from (1) certification bodies and (2) test laboratories with experience in programs for similar types of electronic equipment. Additional preferred knowledge includes experience with incar video systems or experience with law enforcement operations. There are up to four positions to be filled on the STC, and NIJ will accept the first 20 submissions for review. Interested parties are requested to nominate individuals from their organizations and submit no more than two pages describing the nominee’s applicable experience, preferred knowledge, and affiliations with standards development organizations. This information shall be submitted to Frances Scott at frances.scott@usdoj.gov by December 22, 2009. The submissions will be reviewed, and participants will be notified regarding their acceptance by January 8, 2009. FOR FURTHER INFORMATION CONTACT: Casandra Robinson by telephone at 202– 305–2296 [Note: this is not a toll-free E:\FR\FM\11DEN1.SGM 11DEN1

Agencies

[Federal Register Volume 74, Number 237 (Friday, December 11, 2009)]
[Notices]
[Page 65789]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-29527]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on September 28, 2009, Cedarburg 
Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, 
made application by renewal to the Drug Enforcement Administration 
(DEA) as a bulk manufacturer of the basic classes of controlled 
substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
Dihydromorphine (9145).....................  I
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    In reference to drug code 7370 the company plans to bulk 
manufacture a synthetic Tetrahydrocannabinol. No other activity for 
this drug code is authorized for this registration.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than February 9, 2010.

    Dated: December 1, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-29527 Filed 12-10-09; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.